Orgenesis Net Income vs Research Development Analysis
ORGS Stock | USD 0.55 0.02 3.77% |
Orgenesis financial indicator trend analysis is much more than just breaking down Orgenesis prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Orgenesis is a good investment. Please check the relationship between Orgenesis Net Income and its Research Development accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Orgenesis. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. For more information on how to buy Orgenesis Stock please use our How to Invest in Orgenesis guide.
Net Income vs Research Development
Net Income vs Research Development Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Orgenesis Net Income account and Research Development. At this time, the significance of the direction appears to have pay attention.
The correlation between Orgenesis' Net Income and Research Development is -0.86. Overlapping area represents the amount of variation of Net Income that can explain the historical movement of Research Development in the same time period over historical financial statements of Orgenesis, assuming nothing else is changed. The correlation between historical values of Orgenesis' Net Income and Research Development is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Income of Orgenesis are associated (or correlated) with its Research Development. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Research Development has no effect on the direction of Net Income i.e., Orgenesis' Net Income and Research Development go up and down completely randomly.
Correlation Coefficient | -0.86 |
Relationship Direction | Negative |
Relationship Strength | Significant |
Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Orgenesis financial statement analysis. It represents the amount of money remaining after all of Orgenesis operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Research Development
Most indicators from Orgenesis' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Orgenesis current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Orgenesis. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. For more information on how to buy Orgenesis Stock please use our How to Invest in Orgenesis guide.At this time, Orgenesis' Discontinued Operations is comparatively stable compared to the past year. Issuance Of Capital Stock is likely to gain to about 5.9 M in 2024, whereas Tax Provision is likely to drop (87.2 K) in 2024.
2023 | 2024 (projected) | Reconciled Depreciation | 1.7M | 1.7M | Interest Income | 31.5K | 29.9K |
Orgenesis fundamental ratios Correlations
Click cells to compare fundamentals
Orgenesis Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Orgenesis fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 73.9M | 77.7M | 59.8M | 90.9M | 14.6M | 38.8M | |
Other Current Liab | 6.8M | 2.3M | 2.4M | 4.7M | 4.1M | 7.1M | |
Total Current Liabilities | 17.2M | 16.3M | 15.4M | 15.9M | 16.4M | 11.9M | |
Total Stockholder Equity | 26.1M | 52.6M | 38.5M | 27.6M | (21.0M) | 27.4M | |
Net Debt | (32.0M) | 6.4M | 15.0M | 21.8M | 25.1M | 26.3M | |
Retained Earnings | (65.2M) | (88.3M) | (106.4M) | (121.3M) | (176.6M) | (68.4M) | |
Accounts Payable | 4.6M | 8.6M | 5.2M | 4.4M | 6.6M | 3.7M | |
Cash | 14.6M | 44.9M | 5.5M | 5.3M | 837K | 15.3M | |
Cash And Short Term Investments | 14.6M | 44.9M | 5.5M | 5.3M | 837K | 15.3M | |
Common Stock Shares Outstanding | 21.3M | 24.3M | 25.1M | 29.0M | 33.4M | 35.0M | |
Liabilities And Stockholders Equity | 77.7M | 59.8M | 90.9M | 14.6M | 16.7M | 15.9M | |
Other Stockholder Equity | 669K | 140.1M | 144.7M | 149.1M | 155.6M | 635.6K | |
Total Liab | 47.8M | 25.0M | 21.2M | 31.7M | 35.5M | 25.6M | |
Total Current Assets | 28.1M | 50.1M | 25.8M | 46.3M | 4.1M | 15.1M | |
Non Current Assets Total | 27.6M | 34.1M | 44.6M | 10.5M | 12.0M | 11.4M | |
Other Current Assets | 387K | 1.7M | 1.7M | 4.7M | 3.1M | 367.7K | |
Intangible Assets | 16.6M | 13.0M | 11.8M | 9.7M | 7.4M | 9.9M | |
Other Liab | 2.2M | 387K | 389K | 578K | 2.0M | 2.5M | |
Property Plant And Equipment Net | 4.5M | 11.3M | 25.1M | 1.8M | 2.1M | 2.0M | |
Non Currrent Assets Other | 440K | 821K | 805K | 1.4M | 18K | 708.5K | |
Other Assets | 1.3M | 1.5M | 2.8M | 8.6M | 1.7M | 1.8M | |
Net Receivables | 3.2M | 3.3M | 18.5M | 39.8M | 2.6M | 3.1M | |
Non Current Liabilities Total | 8.7M | 5.8M | 15.7M | 19.1M | 22.0M | 16.6M | |
Inventory | 1.7M | 185K | 118K | 120K | 34K | 1.7M | |
Property Plant And Equipment Gross | 12.5M | 4.5M | 11.3M | 29.1M | 2.4M | 10.1M | |
Property Plant Equipment | 11.9M | 12.5M | 4.3M | 5.1M | 14.3M | 15.0M | |
Short Long Term Debt Total | 4.8M | 12.9M | 11.8M | 20.3M | 22.6M | 4.5M | |
Accumulated Other Comprehensive Income | 1M | 748K | 207K | (270K) | 65K | 1.1M | |
Short Term Debt | 753K | 4.6M | 6.4M | 5.1M | 3.6M | 715.4K | |
Net Tangible Assets | (5.8M) | 30.8M | 18.3M | 9.7M | (6.7M) | (6.3M) | |
Current Deferred Revenue | 751K | 1.3M | 1.6M | 2.2M | 2.5M | 3.6M | |
Short Long Term Debt | 753K | 4.1M | 5.9M | 4.5M | 3.3M | 715.4K | |
Long Term Debt | 2.8M | 7.3M | 4.9M | 13.3M | 19.0M | 2.7M | |
Good Will | 15.3M | 8.7M | 8.4M | 8.2M | 1.2M | 8.1M |
Pair Trading with Orgenesis
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Orgenesis position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Orgenesis will appreciate offsetting losses from the drop in the long position's value.Moving against Orgenesis Stock
0.56 | MRK | Merck Company Financial Report 6th of August 2024 | PairCorr |
The ability to find closely correlated positions to Orgenesis could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Orgenesis when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Orgenesis - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Orgenesis to buy it.
The correlation of Orgenesis is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Orgenesis moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Orgenesis moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Orgenesis can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Orgenesis. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. For more information on how to buy Orgenesis Stock please use our How to Invest in Orgenesis guide.Note that the Orgenesis information on this page should be used as a complementary analysis to other Orgenesis' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Complementary Tools for Orgenesis Stock analysis
When running Orgenesis' price analysis, check to measure Orgenesis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Orgenesis is operating at the current time. Most of Orgenesis' value examination focuses on studying past and present price action to predict the probability of Orgenesis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Orgenesis' price. Additionally, you may evaluate how the addition of Orgenesis to your portfolios can decrease your overall portfolio volatility.
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |
Is Orgenesis' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Orgenesis. If investors know Orgenesis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Orgenesis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.99) | Revenue Per Share 0.018 | Quarterly Revenue Growth (0.99) | Return On Assets (0.62) | Return On Equity (3.39) |
The market value of Orgenesis is measured differently than its book value, which is the value of Orgenesis that is recorded on the company's balance sheet. Investors also form their own opinion of Orgenesis' value that differs from its market value or its book value, called intrinsic value, which is Orgenesis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Orgenesis' market value can be influenced by many factors that don't directly affect Orgenesis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Orgenesis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Orgenesis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Orgenesis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.